跳至主要内容
临床试验/NCT01186692
NCT01186692已完成不适用

Implantation of the Medtronic Melody Transcatheter Pulmonary Valve (TPV) in Patients With Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduits: A Post-Market Approval Study

Medtronic Cardiovascular20 个研究点 分布在 1 个国家目标入组 131 人开始时间: 2010年7月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
131
试验地点
20
主要终点
Acceptable TPV Hemodynamic Function at Six Months After Successful TPV Implantation

研究概览

简要总结

The purpose of this study is to confirm the short-term hemodynamic effectiveness results achieved by real-world providers are equivalent to the historical control established in the IDE study.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Existence of a full (circumferential) RVOT conduit that was equal to or greater than 16 mm in diameter when originally implanted
  • Dysfunctional RVOT conduits with a clinical indication for intervention (regurgitation ≥ moderate regurgitation, Stenosis: mean RVOT gradient ≥ 35 mmHg)

排除标准

  • Implantation in the aortic or mitral position
  • Venous anatomy unable to accommodate a 22-fr size introducer sheath
  • Obstruction of the central veins
  • Clinical or biological signs of infection including active endocarditis
  • Unwilling or unable to provide written informed consent or comply with the follow-up requirements

研究组 & 干预措施

Melody TPV Implant

Experimental

Melody® Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.

干预措施: Melody® Transcatheter Pulmonary Valve (Device)

结局指标

主要结局

Acceptable TPV Hemodynamic Function at Six Months After Successful TPV Implantation

时间窗: 6 months

Acceptable TPV hemodynamic function at six months after successful TPV implantation is determined as a composite of the following: * Mean RVOT gradient is less than or equal to 30 mmHg as measured by CW Doppler, and * Severity of pulmonary regurgitation is less than moderate by Doppler echocardiography, and * Free from RVOT conduit reoperation or catheter re-intervention at six months after TPV implantation. The endpoint is defined as the percentage of subjects with acceptable TPV hemodynamic function at six months after Melody valve implantation.

次要结局

  • Serious Device-related Adverse Events(6 months)
  • Changes in NYHA Functional Classification(6 Months)
  • Procedural Success(6 Months)
  • Serious Procedural Adverse Events(6 Months)

研究者

发起方
Medtronic Cardiovascular
申办方类型
Industry
责任方
Sponsor

研究点 (20)

Loading locations...

相似试验